{
    "paper_id": "d27842f2883b8884d975fe744e1157bb727d6f9b",
    "metadata": {
        "title": "ScienceDirect Prise en charge des exacerbations : de la ville \u00e0 l'h\u00f4pital \u0b1d,\u0b1d\u0b1d Management of COPD exacerbations: From primary care to hospitalization",
        "authors": [
            {
                "first": "St\u00e9phane",
                "middle": [],
                "last": "Jouneau",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "H\u00f4pital Pontchaillou",
                    "location": {
                        "addrLine": "universit\u00e9 de Rennes 1, service de pneumologie",
                        "postCode": "35033",
                        "settlement": "Rennes",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Graziella",
                "middle": [],
                "last": "Brinchault",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "H\u00f4pital Pontchaillou",
                    "location": {
                        "addrLine": "universit\u00e9 de Rennes 1, service de pneumologie",
                        "postCode": "35033",
                        "settlement": "Rennes",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Beno\u00eet",
                "middle": [],
                "last": "Desrues",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "H\u00f4pital Pontchaillou",
                    "location": {
                        "addrLine": "universit\u00e9 de Rennes 1, service de pneumologie",
                        "postCode": "35033",
                        "settlement": "Rennes",
                        "country": "France"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Points essentiels La Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise d\u00e9finie l'exacerbation aigu\u00eb de bronchopneumopathie chronique obstructive comme une majoration des sympt\u00f4mes respiratoires au-del\u00e0 des variations quotidiennes (en pratique, d'une dur\u00e9e \u2265 48 h ou justifiant une modification th\u00e9rapeutique).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "La cause de ces exacerbations est principalement infectieuse : virale (rhinovirus, virus influenzae et parainfluenzae, coronavirus, ad\u00e9novirus et virus respiratoire syncytial) ou bact\u00e9rienne (principalement, Haemophilus influenzae, Streptococcus pneumoniae et Moraxella catarrhalis). Elles peuvent \u00e9galement r\u00e9sulter de l'exposition \u00e0 certains polluants : NO 2 , SO 2 , ozone et pollution particulaire (PM10 et PM2, 5) . Elle reste ind\u00e9termin\u00e9e dans pr\u00e8s de 30 % des cas.",
            "cite_spans": [
                {
                    "start": 416,
                    "end": 418,
                    "text": "5)",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Les diagnostics diff\u00e9rentiels incluent les pneumopathies infectieuses, les pneumothorax, les pouss\u00e9es d'insuffisance cardiaque et les embolies pulmonaires.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "La pr\u00e9sence de signes de gravit\u00e9 conditionne l'hospitalisation : signes d'insuffisance respiratoire aigu\u00eb, de choc ou de d\u00e9faillance neurologique, mais aussi en cas de patient fragile, d'absence de soutien familial \u00e0 domicile ou de r\u00e9ponse au traitement initial. \u0b1d Ne pas utiliser, pour citation, la r\u00e9f\u00e9rence de cet article mais la r\u00e9f\u00e9rence de sa premi\u00e8re parution : La Presse m\u00e9dicale (2014) 43, Prise en charge des exacerbations : de la ville \u00e0 l'h\u00f4pital 49 Le traitement consiste en une majoration des bronchodilatateurs, une kin\u00e9sith\u00e9rapie respiratoire, une antibioth\u00e9rapie en cas d'expectoration franchement purulente. La prescription de cortico\u00efdes syst\u00e9miques ne doit pas \u00eatre syst\u00e9matique. La dose recommand\u00e9e est de 0,5 mg/kg sur une courte p\u00e9riode (5-7 jours). Lors d'une hospitalisation, une oxyg\u00e9noth\u00e9rapie et une thromboprophylaxie peuvent \u00eatre instaur\u00e9es. La ventilation non invasive est principalement indiqu\u00e9e en cas de persistance d'une hypercapnie malgr\u00e9 un traitement m\u00e9dical optimal. Que le patient soit pris en charge en ambulatoire ou en hospitalisation, une r\u00e9\u00e9valuation clinique \u00e0 48-72 h est indispensable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Key points The Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise defines acute exacerbation of chronic obstructive pulmonary disease (AE COPD) as an increase in daily respiratory symptoms, basically duration \u2265 48h or need for treatment adjustment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Etiology of EA COPD are mainly infectious, viral (rhinovirus, influenzae or parainfluenzae virus, coronavirus, adenovirus and respiratory syncytial virus) or bacterial (Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis). Pollutant exposure can also lead to AE COPD, such as NO 2 , SO 2 , ozone or particulates (PM10 and PM2.5). In 30% the etiology remains unknown.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Differential diagnoses of AE COPD include infectious pneumonia, pneumothorax, acute heart failure and pulmonary embolism.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Presences of signs of severity impose hospitalization: signs of respiratory distress, shock, acute confusion but also fragile patients, insufficient home support or absence of response to initial treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "AE COPD treatments consist on increase in bronchodilators, chest physiotherapy, and antibiotics if sputum is frankly purulent. Systemic corticosteroids should not be systematic. Recommended dose is 0.5 mg/kg on short course (5-7 days). During hospitalization, oxygen supplementation and thromboprophylaxis could be prescribed. The main interest in non-invasive ventilation is persistent hypercapnia despite optimal medical management. During ambulatory management or hospitalization, clinical assessment at 48-72 h is mandatory.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "L'exacerbation aigu\u00eb de bronchopneumopathie chronique obstructive (EA BPCO) repr\u00e9sente un \u00e9v\u00e9nement important dans l'histoire naturelle de la BPCO, notamment en cas d'hospitalisation. Les EA BPCO interviennent dans la gravit\u00e9 et l'\u00e9volution de la maladie ; et leur pr\u00e9vention est un des objectifs principal des traitements de fond.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "En l'absence de consensus international [1] , la SPLF a d\u00e9fini l'EA BPCO comme une majoration des sympt\u00f4mes respiratoires au-del\u00e0 des variations quotidiennes (en pratique, d'une dur\u00e9e \u2265 48 h ou justifiant une modification th\u00e9rapeutique) [2] . Les crit\u00e8res couramment utilis\u00e9s sont l'augmentation de la dyspn\u00e9e, de la toux, du volume de l'expectoration ou la modification de l'expectoration (aspect purulent). Le diagnostic est donc clinique, bas\u00e9 sur les donn\u00e9es d'interrogatoire. L'EA BPCO peut \u00eatre un mode de d\u00e9couverte de la BPCO. On nomme d\u00e9compensations de BPCO, les EA susceptibles d'engager le pronostic vital [2] .",
            "cite_spans": [
                {
                    "start": 40,
                    "end": 43,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 237,
                    "end": 240,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 618,
                    "end": 621,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "ref_spans": [],
            "section": "D\u00e9finition"
        },
        {
            "text": "On parle d'exacerbations fr\u00e9quentes, \u00e0 partir de 2 \u00e9pisodes d'EA au cours des 12 derniers mois [3] .",
            "cite_spans": [
                {
                    "start": 95,
                    "end": 98,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "D\u00e9finition"
        },
        {
            "text": "La BPCO est aujourd'hui la 2 e maladie respiratoire apr\u00e8s l'asthme et la 6 e cause de mortalit\u00e9 en France. Elle concerne 5 \u00e0 10 % de la population adulte. Seulement 20 \u00e0 30 % des cas sont diagnostiqu\u00e9s et 10 \u00e0 15 % pris en charge. Elle sera la 4 e cause de mortalit\u00e9 dans le monde en 2030 [4] .",
            "cite_spans": [
                {
                    "start": 289,
                    "end": 292,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie"
        },
        {
            "text": "Les patients exacerbateurs fr\u00e9quents ont \u00e9galement une augmentation de la pr\u00e9valence des comorbidit\u00e9s extrapulmonaires incluant les maladies cardiovasculaires, le reflux gastro-oesophagien, la d\u00e9pression, l'ost\u00e9oporose et l'alt\u00e9ration des fonctions cognitives [5] .",
            "cite_spans": [
                {
                    "start": 260,
                    "end": 263,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie"
        },
        {
            "text": "Ces patients ont ainsi une qualit\u00e9 de vie alt\u00e9r\u00e9e, un d\u00e9clin acc\u00e9l\u00e9r\u00e9 de leur VEMS, une augmentation de leurs hospitalisations (et de leur mortalit\u00e9), contribuant \u00e0 augmenter la susceptibilit\u00e9 \u00e0 une nouvelle exacerbation perp\u00e9tuant le ph\u00e9notype d'exacerbateur fr\u00e9quent [5] .",
            "cite_spans": [
                {
                    "start": 269,
                    "end": 272,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie"
        },
        {
            "text": "L'EA BPCO est un \u00e9l\u00e9ment pronostique important. En effet, 45 % des patients d\u00e9c\u00e8dent dans les 4 ans qui suivent une hospitalisation pour EA BPCO [6] . Parmi les facteurs de risque de d\u00e9c\u00e8s (analyse multivari\u00e9e) \u00e9taient retrouv\u00e9s : l'\u00e2ge \u2265 80 ans, un indice de masse corporelle (IMC) \u2264 20 kg/m 2 , un ant\u00e9c\u00e9dent de cancer bronchique ou d'hospitalisation pour EA BPCO, les comorbidit\u00e9s cardiovasculaires, la mise en jeu des muscles respiratoires accessoires ou un oed\u00e8me des membres inf\u00e9rieurs \u00e0 l'admission, et l'oxyg\u00e9noth\u00e9rapie au long cours instaur\u00e9e \u00e0 la sortie de l'hospitalisation.",
            "cite_spans": [
                {
                    "start": 145,
                    "end": 148,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie"
        },
        {
            "text": "Le diagnostic positif d'une EA BPCO est bas\u00e9 sur les crit\u00e8res de d\u00e9finition : majoration de la dyspn\u00e9e et/ou de la toux et/ou de l'expectoration (volume, purulence) sur plus de 2 jours ou avec modification th\u00e9rapeutique [2] . D'autres sympt\u00f4mes peuvent \u00eatre pr\u00e9sents tels que sibilants, sensation d'oppression thoracique, oed\u00e8me des membres inf\u00e9rieurs ou asth\u00e9nie. Une douleur thoracique ou de la fi\u00e8vre ne sont pas classiques [7] .",
            "cite_spans": [
                {
                    "start": 220,
                    "end": 223,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 427,
                    "end": 430,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Diagnostic positif"
        },
        {
            "text": "Certains facteurs sont connus pour entra\u00eener des EA BPCO (figure 1).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Diagnostic \u00e9tiologique"
        },
        {
            "text": "Les infections des voies a\u00e9riennes basses repr\u00e9sentent la cause la plus fr\u00e9quente. Les infections virales des voies a\u00e9riennes sup\u00e9rieures sont souvent incrimin\u00e9es comme facteur d\u00e9clenchant des EA BPCO, surtout durant la p\u00e9riode hivernale [8] . Les virus les plus fr\u00e9quemment rencontr\u00e9s sont les rhinovirus (virus du \u00ab rhume \u00bb, le plus fr\u00e9quent), les virus influenzae (virus de la grippe) et parainfluenzae, les coronavirus, les ad\u00e9novirus et le virus respiratoire syncytial [7, 8] . Ils augmentent l'inflammation des voies a\u00e9riennes inf\u00e9rieures (interleukines [IL]-6, IL-8) et participent au stress oxydatif [8] .",
            "cite_spans": [
                {
                    "start": 238,
                    "end": 241,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 474,
                    "end": 477,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 478,
                    "end": 480,
                    "text": "8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 608,
                    "end": 611,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": "Diagnostic \u00e9tiologique"
        },
        {
            "text": "Bien que des bact\u00e9ries puissent coloniser les voies a\u00e9riennes inf\u00e9rieures des patients \u00e0 l'\u00e9tat stable (\u2248 30 %) [5] , elles sont \u00e9galement responsables d'EA BPCO, en particulier en cas d'acquisition de nouvelles souches bact\u00e9riennes [9] . Les principales bact\u00e9ries responsables d'EA BPCO sont Haemophilus influenzae, Streptococcus pneumoniae et Moraxella catarrhalis [7, 9, 10] . Chez les patients les plus s\u00e9v\u00e8res il faut savoir rechercher certaines bact\u00e9ries particuli\u00e8res telles que Pseudomonas aeruginosa ou Staphylococcus aureus [11] . Des bact\u00e9ries intracellulaires telles que Chlamydia pneumoniae pourraient \u00e9galement jouer un r\u00f4le dans les EA BPCO. On retrouve une co-infection virus-bact\u00e9rie dans un quart des EA BPCO [5] .",
            "cite_spans": [
                {
                    "start": 112,
                    "end": 115,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 233,
                    "end": 236,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 367,
                    "end": 370,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 371,
                    "end": 373,
                    "text": "9,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 374,
                    "end": 377,
                    "text": "10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 534,
                    "end": 538,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 727,
                    "end": 730,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Diagnostic \u00e9tiologique"
        },
        {
            "text": "Les pics de pollution urbaine sont \u00e9galement des facteurs d'exacerbation. Les polluants les plus communs sont repr\u00e9sent\u00e9s par le NO 2 , le SO 2 , l'ozone et les particules de diam\u00e8tres inf\u00e9rieurs \u00e0 10 m (PM10) et inf\u00e9rieur \u00e0 2,5 m (PM 2,5) [8] . Les m\u00e9canismes physiopathologiques exacts reliant la pollution aux EA BPCO ne sont pas \u00e9lucid\u00e9s, mais impliqueraient une plus grande susceptibilit\u00e9 aux infections virales [8] .",
            "cite_spans": [
                {
                    "start": 240,
                    "end": 243,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 417,
                    "end": 420,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": "Diagnostic \u00e9tiologique"
        },
        {
            "text": "Enfin, dans environ 30 % des cas, l'origine des EA BPCO n'est pas identifi\u00e9e [7] .",
            "cite_spans": [
                {
                    "start": 77,
                    "end": 80,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Diagnostic \u00e9tiologique"
        },
        {
            "text": "Les EA BPCO sont \u00e0 diff\u00e9rencier d'autres complications ou affections aigu\u00ebs survenant assez fr\u00e9quemment dans la BPCO. Ce sont principalement les pneumothorax, les pouss\u00e9es d'insuffisance cardiaque et les embolies pulmonaires. La fr\u00e9quence de ces derni\u00e8res est variable au cours des EA BPCO, mais para\u00eet \u00e9lev\u00e9e (25 %) chez les malades hospitalis\u00e9s pour exacerbation [12] . Il n'existe pas de signes clinique, biologique ou radiologique sp\u00e9cifiques de maladie veineuse thromboembolique, mais elle doit \u00eatre suspect\u00e9e devant une EA BPCO avec douleur thoracique ou syncope, ou devant une diminution de la capnie chez un patient habituellement hypercapnique [13] . La maladie veineuse thromboembolique prolonge une hospitalisation pour EA BPCO de 4,4 jours en moyenne et augmente la mortalit\u00e9 \u00e0 1 an de 30 %. L'absence de diagnostic et d'instauration d'une anticoagulation curative augmente la mortalit\u00e9 de 25 % durant l'hospitalisation [13] .",
            "cite_spans": [
                {
                    "start": 365,
                    "end": 369,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 653,
                    "end": 657,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 932,
                    "end": 936,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "ref_spans": [],
            "section": "Diagnostic diff\u00e9rentiel"
        },
        {
            "text": "Les pneumopathies infectieuses sont \u00e9galement \u00e0 diff\u00e9rencier d'une EA BPCO. Leur diagnostic est suspect\u00e9 en cas de fi\u00e8vre \u00e9lev\u00e9e (> 38,5 \u2022 C) ou de signes focalis\u00e9s \u00e0 l'auscultation (souffle tubaire, foyer de cr\u00e9pitants) et confirm\u00e9 par la pr\u00e9sence d'opacit\u00e9 syst\u00e9matis\u00e9e sur la radiographie thoracique.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Diagnostic diff\u00e9rentiel"
        },
        {
            "text": "Les EA BPCO sont associ\u00e9es \u00e0 une augmentation de l'inflammation syst\u00e9mique (CRP, fibrinog\u00e8ne, leucocytes, IL-6, IL-8, tumor necrosis factor [TNF]\u2423) et de l'inflammation des voies a\u00e9riennes inf\u00e9rieures (IL-6, IL-8, TNF\u2423) (figure 1) [1, 14] . Chez les exacerbateurs fr\u00e9quents et les patients avec colonisation bact\u00e9rienne, on retrouve un niveau d'inflammation bronchique basale plus \u00e9lev\u00e9 que chez les non-exacerbateurs fr\u00e9quents [8] . Les EA BPCO d'origine virale semblent associ\u00e9es \u00e0 une inflammation syst\u00e9mique et bronchique plus \u00e9lev\u00e9e avec un temps de retour \u00e0 l'\u00e9tat de base plus long [5] .",
            "cite_spans": [
                {
                    "start": 231,
                    "end": 234,
                    "text": "[1,",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 235,
                    "end": 238,
                    "text": "14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 428,
                    "end": 431,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 589,
                    "end": 592,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Physiopathologie, facteurs de risque"
        },
        {
            "text": "La fr\u00e9quence des EA BPCO semble augmenter avec la s\u00e9v\u00e9rit\u00e9 de la BPCO jug\u00e9e sur le stade GOLD [3] . D'autre part, les EA BPCO semblent \u00e9galement acc\u00e9l\u00e9rer le d\u00e9clin de la fonction respiratoire, diminuer la qualit\u00e9 de vie, r\u00e9duire la force musculaire p\u00e9riph\u00e9rique et augmenter la mortalit\u00e9 [5] .",
            "cite_spans": [
                {
                    "start": 94,
                    "end": 97,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 289,
                    "end": 292,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Physiopathologie, facteurs de risque"
        },
        {
            "text": "Enfin, plusieurs comorbidit\u00e9s semblent associ\u00e9es au ph\u00e9notype \u00ab exacerbateur fr\u00e9quent \u00bb : nombreuses comorbidit\u00e9s cardiovasculaires incluant ath\u00e9roscl\u00e9rose, cardiopathie isch\u00e9mique, hypertension art\u00e9rielle, insuffisance cardiaque, accident vasculaire c\u00e9r\u00e9bral ; le reflux gastro-oesophagien ; l'anxi\u00e9t\u00e9 et la d\u00e9pression et l'ost\u00e9oporose [5] .",
            "cite_spans": [
                {
                    "start": 337,
                    "end": 340,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Physiopathologie, facteurs de risque"
        },
        {
            "text": "Le meilleur traitement des EA BPCO est la pr\u00e9vention. Elle rel\u00e8ve du sevrage tabagique, des vaccinations antigrippale et antipneumococcique, des traitements de fond inhal\u00e9s ou Le traitement curatif est principalement bas\u00e9 sur les bronchodilatateurs, la kin\u00e9sith\u00e9rapie de drainage bronchique et \u00e9ventuellement l'antibioth\u00e9rapie, la corticoth\u00e9rapie syst\u00e9mique et l'oxyg\u00e9noth\u00e9rapie [7, 10, 15] . Que ce soit en ambulatoire ou en hospitalisation, la th\u00e9ophylline, les mucomodificateurs (type N-ac\u00e9tyl-cyst\u00e9ine, carbocyst\u00e9ine) ou les analeptiques respiratoires n'ont pas d'indication [15] . Les antitussifs ou les neuros\u00e9datifs sont contre-indiqu\u00e9s [15] .",
            "cite_spans": [
                {
                    "start": 379,
                    "end": 382,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 383,
                    "end": 386,
                    "text": "10,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 387,
                    "end": 390,
                    "text": "15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 579,
                    "end": 583,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 644,
                    "end": 648,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Prise en charge"
        },
        {
            "text": "En pratique, devant un patient ayant une EA BPCO, il faut \u00e9valuer rapidement le degr\u00e9 de gravit\u00e9 (encadr\u00e9 1), en comparant l'importance des nouveaux sympt\u00f4mes par rapport aux signes habituels de la maladie [7, 15] . Si les donn\u00e9es de la gazom\u00e9trie art\u00e9rielle \u00e0 l'\u00e9tat de base sont disponibles, la comparaison est \u00e9galement essentielle. S'il n'existe pas de crit\u00e8re de gravit\u00e9, la prise en charge peut \u00eatre assur\u00e9e au domicile du patient par le m\u00e9decin g\u00e9n\u00e9raliste. Les comorbidit\u00e9s, l'\u00e2ge et l'entourage au domicile sont \u00e9galement \u00e0 prendre en compte lors de la d\u00e9cision d'hospitaliser ou non un patient. ",
            "cite_spans": [
                {
                    "start": 206,
                    "end": 209,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 210,
                    "end": 213,
                    "text": "15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Prise en charge"
        },
        {
            "text": "Le diagnostic d'EA BPCO est clinique. Aucun examen compl\u00e9mentaire n'est indiqu\u00e9 en premi\u00e8re intention, notamment pas d'examen cytobact\u00e9riologique des crachats (ECBC) ni de radiographie thoracique, sauf en cas de fi\u00e8vre \u00e9lev\u00e9e pour ne pas m\u00e9conna\u00eetre une pneumopathie aigu\u00eb communautaire [7, 10] .",
            "cite_spans": [
                {
                    "start": 287,
                    "end": 290,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 291,
                    "end": 294,
                    "text": "10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [],
            "section": "En ambulatoire"
        },
        {
            "text": "Une \u00e9tude de cohorte a montr\u00e9 que le traitement pr\u00e9coce des EA BPCO r\u00e9duisait le risque d'hospitalisation [16] . Il faut donc bien insister sur l'\u00e9ducation du patient \u00e0 la reconnaissance des signes d'EA BPCO pour que leur prise en charge ambulatoire soit la plus pr\u00e9coce possible.",
            "cite_spans": [
                {
                    "start": 106,
                    "end": 110,
                    "text": "[16]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "En ambulatoire"
        },
        {
            "text": "Le traitement bronchodilatateur doit \u00eatre intensifi\u00e9, soit en augmentant les doses habituelles soit \u00e9ventuellement en associant plusieurs classes de bronchodilatateurs. Lors des EA BPCO, l'utilisation d'une chambre inhalation avec un spray semble aussi efficace que les n\u00e9bulisations de bronchodilatateurs [17] . La kin\u00e9sith\u00e9rapie respiratoire de drainage bronchique est indiqu\u00e9e en cas d'encombrement (difficult\u00e9 \u00e0 \u00e9vacuer les s\u00e9cr\u00e9tions) [15] . Lorsque l'augmentation de la dyspn\u00e9e s'accompagne d'une expectoration purulente, il est recommand\u00e9 de prescrire une antibioth\u00e9rapie [18, 19] . L'antibiotique prescrit doit \u00eatre actif sur les principaux germes : H. influenzae, S. pneumoniae et M. catarrhalis [10] . La prise de cortico\u00efdes par voie orale \u00e0 la dose de 0,5 mg/kg/j de prednisolone ou \u00e9quivalent pendant 10 jours raccourcirait la dur\u00e9e des exacerbations selon une seule \u00e9tude sur un tr\u00e8s faible effectif [20] . Une \u00e9tude randomis\u00e9e en double aveugle a \u00e9galement montr\u00e9 que les patients trait\u00e9s, en plus des antibiotiques et bronchodilatateurs, par 40 mg/j de prednisone pendant les 10 jours qui suivent leur sortie des urgences avaient significativement moins de dyspn\u00e9e et un meilleur VEMS que ceux sous placebo [21] . Au final, la corticoth\u00e9rapie syst\u00e9mique au cours d'une EA BPCO (0,5 mg/kg/j pendant 7 jours), n'est donc pas recommand\u00e9e pour toutes les exacerbations, mais doit \u00eatre r\u00e9serv\u00e9e aux \u00e9checs de la prise en charge initiale [15, 22] . Dans tous les cas, la prise en charge th\u00e9rapeutique est r\u00e9\u00e9valu\u00e9e \u00e0 24-72 heures (figure 2) [15] .",
            "cite_spans": [
                {
                    "start": 306,
                    "end": 310,
                    "text": "[17]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 440,
                    "end": 444,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 579,
                    "end": 583,
                    "text": "[18,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 584,
                    "end": 587,
                    "text": "19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 705,
                    "end": 709,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 914,
                    "end": 918,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1223,
                    "end": 1227,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1448,
                    "end": 1452,
                    "text": "[15,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1453,
                    "end": 1456,
                    "text": "22]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 1551,
                    "end": 1555,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "En ambulatoire"
        },
        {
            "text": "Le traitement des exacerbations graves doit \u00eatre r\u00e9alis\u00e9 en milieu hospitalier. Les crit\u00e8res d'hospitalisation sont essentiellement cliniques et portent sur la gravit\u00e9 des sympt\u00f4mes et les ant\u00e9c\u00e9dents du patient (encadr\u00e9 1).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c0 l'h\u00f4pital"
        },
        {
            "text": "Des examens compl\u00e9mentaires sont faits \u00e0 l'admission [7] : radiographie thoracique, principalement pour \u00e9carter les diagnostics diff\u00e9rentiels ; gazom\u00e9trie art\u00e9rielle ; \u00e9lectrocardiogramme (ECG) ; biologie basale simple incluant NFS, ionogramme sanguin, ur\u00e9e, cr\u00e9atinin\u00e9mie ; ECBC si l'expectoration est purulente ; h\u00e9mocultures si le patient est f\u00e9brile. Les dosages de CRP et de NT-proBNP ne font partie d'aucune recommandation nationale ou internationale dans la prise en charge des EA BPCO.",
            "cite_spans": [
                {
                    "start": 53,
                    "end": 56,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "\u00c0 l'h\u00f4pital"
        },
        {
            "text": "D\u00e8s l'admission \u00e0 l'h\u00f4pital, il faut d\u00e9terminer si le patient doit \u00eatre hospitalis\u00e9 en r\u00e9animation, d\u00e9cision bas\u00e9e sur les signes cliniques et sur la gazom\u00e9trie art\u00e9rielle r\u00e9alis\u00e9e id\u00e9alement au d\u00e9bit d'oxyg\u00e8ne habituel du patient. Les crit\u00e8res d'hospitalisation en r\u00e9animation sont la pr\u00e9sence d'une dyspn\u00e9e de repos avec une tachypn\u00e9e importante, de troubles de la conscience ainsi que d'une acidose respiratoire s\u00e9v\u00e8re ne r\u00e9pondant pas au traitement instaur\u00e9 en urgence. Chez ce type de patients, si une ventilation m\u00e9canique n'est pas institu\u00e9e rapidement, le risque de d\u00e9c\u00e8s est tr\u00e8s \u00e9lev\u00e9.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c0 l'h\u00f4pital"
        },
        {
            "text": "Une oxyg\u00e9noth\u00e9rapie est d\u00e9but\u00e9e si n\u00e9cessaire afin de maintenir la saturation art\u00e9rielle en O 2 (SaO 2 ) \u2265 90 %. Elle est administr\u00e9e \u00e0 l'aide de lunettes nasales ou d'un masque Venturi [23, 24] . Le d\u00e9bit d'oxyg\u00e8ne doit \u00eatre rapidement adapt\u00e9 en fonction de la SpO 2 . Lorsqu'elle se situe entre 90 et 94 %, le d\u00e9bit d'O 2 est maintenu 30 minutes afin de r\u00e9aliser une gazom\u00e9trie art\u00e9rielle de contr\u00f4le. Celle-ci permet de v\u00e9rifier qu'il n'appara\u00eet pas une augmentation importante de la PaCO 2 avec une acidose respiratoire s\u00e9v\u00e8re et de confirmer la correction partielle de l'hypox\u00e9mie (PaO 2 > 60 mmHg ou 8,0 kPa). ",
            "cite_spans": [
                {
                    "start": 186,
                    "end": 190,
                    "text": "[23,",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 191,
                    "end": 194,
                    "text": "24]",
                    "ref_id": "BIBREF23"
                }
            ],
            "ref_spans": [],
            "section": "Oxyg\u00e9noth\u00e9rapie"
        },
        {
            "text": "Les \u24242-agonistes de courte dur\u00e9e d'action en n\u00e9bulisation sont indiqu\u00e9s en premi\u00e8re intention lors des EA BPCO [25] . En l'absence de r\u00e9ponse, on peut y associer du bromure d'ipratropium en n\u00e9bulisation. Le gaz propulseur, qui doit \u00eatre sp\u00e9cifi\u00e9 sur la prescription, doit \u00eatre l'air et non pas l'oxyg\u00e8ne pour ne pas majorer l'hypercapnie [7] .",
            "cite_spans": [
                {
                    "start": 111,
                    "end": 115,
                    "text": "[25]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 338,
                    "end": 341,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Bronchodilatateurs"
        },
        {
            "text": "Plusieurs \u00e9tudes ont montr\u00e9 l'int\u00e9r\u00eat de la corticoth\u00e9rapie syst\u00e9mique en cas d'EA BPCO n\u00e9cessitant une hospitalisation ou un passage aux urgences : r\u00e9duction de la dur\u00e9e d'hospitalisation (24 h en moyenne), am\u00e9lioration plus rapide de la fonction respiratoire et, pour les malades consultant aux urgences puis trait\u00e9s en ambulatoire, r\u00e9duction du taux de rechutes \u00e0 30 jours [20, 21, 26, 27] . Ces premi\u00e8res \u00e9tudes pr\u00e9sentaient certaines limites : les patients ayant d\u00e9j\u00e0 re\u00e7u une corticoth\u00e9rapie syst\u00e9mique avant l'arriv\u00e9e aux urgences \u00e9taient exclus, il n'\u00e9tait retrouv\u00e9 aucun b\u00e9n\u00e9fice \u00e0 moyen terme sur le taux global de succ\u00e8s th\u00e9rapeutiques et, enfin, les effets ind\u00e9sirables n'\u00e9taient pas n\u00e9gligeables (d\u00e9s\u00e9quilibre glyc\u00e9mique, en particulier). N\u00e9anmoins, ces travaux ont montr\u00e9 qu'une dur\u00e9e de corticoth\u00e9rapie sup\u00e9rieure \u00e0 2 semaines n'a pas d'int\u00e9r\u00eat et soulign\u00e9 qu'une dose de 0,5 mg/kg/j de prednisolone est suffisante [26, 27] . Ceci a \u00e9t\u00e9 confirm\u00e9 dans un large essai (n = 314 patients), randomis\u00e9 en double aveugle, qui montrait qu'un traitement court (prednisone 40 mg/jour pendant 5 jours) n'\u00e9tait pas inf\u00e9rieur \u00e0 un traitement long (14 jours) [28] .",
            "cite_spans": [
                {
                    "start": 376,
                    "end": 380,
                    "text": "[20,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 381,
                    "end": 384,
                    "text": "21,",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 385,
                    "end": 388,
                    "text": "26,",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 389,
                    "end": 392,
                    "text": "27]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 930,
                    "end": 934,
                    "text": "[26,",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 935,
                    "end": 938,
                    "text": "27]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 1160,
                    "end": 1164,
                    "text": "[28]",
                    "ref_id": "BIBREF27"
                }
            ],
            "ref_spans": [],
            "section": "Corticoth\u00e9rapie syst\u00e9mique"
        },
        {
            "text": "Lors d'une EA BPCO, une fi\u00e8vre n'est pas pr\u00e9dictive d'une infection bact\u00e9rienne, ce d'autant que l'absence de fi\u00e8vre est classique dans les surinfections bronchiques de BPCO [7, 10] . Les crit\u00e8res d'instauration d'une antibioth\u00e9rapie d\u00e9pendent du terrain du patient, principalement de la s\u00e9v\u00e9rit\u00e9 de sa BPCO (stade GOLD), et du caract\u00e8re purulent de l'expectoration [7, 10, 18, 19] . Pour les BPCO stade 4, l'insuffisance respiratoire est s\u00e9v\u00e8re et m\u00eame si l'origine infectieuse de l'exacerbation est peu probable, la prescription d'antibiotiques est large [10] .",
            "cite_spans": [
                {
                    "start": 174,
                    "end": 177,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 178,
                    "end": 181,
                    "text": "10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 366,
                    "end": 369,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 370,
                    "end": 373,
                    "text": "10,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 374,
                    "end": 377,
                    "text": "18,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 378,
                    "end": 381,
                    "text": "19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 557,
                    "end": 561,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [],
            "section": "Antibioth\u00e9rapie"
        },
        {
            "text": "L'antibiotique prescrit doit \u00eatre actif sur les principaux germes : H. influenzae, S. pneumoniae et M. catarrhalis [10] . Les b\u00eata-lactamines sont probablement les antibiotiques \u00e0 privil\u00e9gier en premi\u00e8re ligne (amoxicilline ou amoxicilline + acide clavulanique, 1 g \u00d7 3/jour pendant 7 jours), suivis de la pristinamycine (1 g \u00d7 3/jour pendant 7 jours). Les avantages de ces deux antibiotiques sont nombreux : recul important sur leur utilisation, relativement bien tol\u00e9r\u00e9s, avec un profil de tol\u00e9rance connu et ils n'ont pas d'impact majeur sur l'\u00e9cologie bact\u00e9rienne [29] . Il faut limiter la prescription des fluoroquinolones actives sur le pneumocoque (FQAP), du fait de l'acquisition rapide de r\u00e9sistance bact\u00e9rienne m\u00eame si ces mol\u00e9cules sont tr\u00e8s actives [30, 31] . En effet, plus le spectre d'une fluoroquinolone est large, plus l'impact sur l'\u00e9cologie bact\u00e9rienne du patient est important [29] .",
            "cite_spans": [
                {
                    "start": 115,
                    "end": 119,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 568,
                    "end": 572,
                    "text": "[29]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 761,
                    "end": 765,
                    "text": "[30,",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 766,
                    "end": 769,
                    "text": "31]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 897,
                    "end": 901,
                    "text": "[29]",
                    "ref_id": "BIBREF28"
                }
            ],
            "ref_spans": [],
            "section": "Antibioth\u00e9rapie"
        },
        {
            "text": "En cas d'\u00e9chec d'une antibioth\u00e9rapie de premi\u00e8re ligne, la r\u00e9alisation d'un ECBC est recommand\u00e9e, notamment pour rechercher des bact\u00e9ries particuli\u00e8res telles que P. aeruginosa ou S. aureus [10, 11] . Le P. aeruginosa a \u00e9t\u00e9 retrouv\u00e9 dans les ECBC de 16 % des patients hospitalis\u00e9s pour une EA BPCO dans deux cohortes prospectives [32, 33] . Dans l'\u00e9tude espagnole, les facteurs de risque d'acqu\u00e9rir cette bact\u00e9rie \u00e9taient un indice de BODE plus \u00e9lev\u00e9, une hospitalisation dans les 12 mois pr\u00e9c\u00e9dents, une corticoth\u00e9rapie orale ou un pr\u00e9c\u00e9dent ECBC positif pour P. aeruginosa. \u00c0 l'avenir, les d\u00e9cisions de mettre en place une antibioth\u00e9rapie pourront s'aider des dosages de procalcitonine, dont l'utilisation permet de r\u00e9duire le nombre d'antibioth\u00e9rapies et leurs dur\u00e9es sans mettre en p\u00e9ril le devenir des malades [34, 35] .",
            "cite_spans": [
                {
                    "start": 190,
                    "end": 194,
                    "text": "[10,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 195,
                    "end": 198,
                    "text": "11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 330,
                    "end": 334,
                    "text": "[32,",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 335,
                    "end": 338,
                    "text": "33]",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 815,
                    "end": 819,
                    "text": "[34,",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 820,
                    "end": 823,
                    "text": "35]",
                    "ref_id": "BIBREF34"
                }
            ],
            "ref_spans": [],
            "section": "Antibioth\u00e9rapie"
        },
        {
            "text": "La prescription d'une thromboprophylaxie doit \u00eatre large lors d'une d\u00e9compensation de BPCO [12, 13, 15] . La kin\u00e9sith\u00e9rapie respiratoire de d\u00e9sencombrement est indiqu\u00e9e [15] . La r\u00e9habilitation pulmonaire peut \u00eatre d\u00e9but\u00e9e au d\u00e9cours d'une EA BPCO, en particulier si elle a conduit \u00e0 une hospitalisation [2, 36] .",
            "cite_spans": [
                {
                    "start": 91,
                    "end": 95,
                    "text": "[12,",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 96,
                    "end": 99,
                    "text": "13,",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 100,
                    "end": 103,
                    "text": "15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 169,
                    "end": 173,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 304,
                    "end": 307,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 308,
                    "end": 311,
                    "text": "36]",
                    "ref_id": "BIBREF35"
                }
            ],
            "ref_spans": [],
            "section": "Autres traitements"
        },
        {
            "text": "La ventilation non invasive (VNI), par masque facial ou nasal, est efficace dans 80 \u00e0 85 % des cas o\u00f9 la ventilation m\u00e9canique est n\u00e9cessaire. C'est le traitement de choix en cas de persistance d'une hypercapnie importante malgr\u00e9 un traitement m\u00e9dical optimal d'une EA BPCO [7] . L'utilisation de la VNI diminue la dur\u00e9e d'hospitalisation, la mortalit\u00e9 et les risques de complications iatrog\u00e8nes (infections nosocomiales, en particulier) [37, 38] . La formation du personnel soignant est indispensable et l'initiation d'une VNI chez un patient souffrant d'une EA BPCO est consommatrice de temps m\u00e9dical mais aussi infirmier [7, 38] . La VNI est plus efficace si utilis\u00e9e t\u00f4t dans la prise en charge d'une EA BPCO. Un pH tr\u00e8s bas, des troubles de conscience marqu\u00e9s, d'importantes comorbidit\u00e9s et un score de gravit\u00e9 \u00e9lev\u00e9 \u00e0 la prise en charge sont autant de facteurs d'\u00e9chec de la VNI [38] . Elle est recommand\u00e9e dans les d\u00e9compensations de BPCO avec acidose respiratoire et pH < 7,35, quelles que soient la cause de la d\u00e9compensation et l'\u00e2ge du patient [39] . M\u00eame si le risque d'\u00e9chec augmente lorsque le pH diminue, la VNI reste utile lorsque le pH est < 7,30. Le mode ventilatoire de premi\u00e8re intention est la VS-AI-PEP [39] . Il est \u00e0 noter que le coma hypercapnique chez un patient souffrant d'une BPCO n'est pas une contre-indication absolue \u00e0 la VNI. Celle-ci peut \u00eatre tent\u00e9e sur une courte p\u00e9riode en esp\u00e9rant diminuer la capnie et ainsi r\u00e9veiller le patient et \u00e9viter une intubation trach\u00e9ale. L'utilisation de la VNI en post-extubation serait particuli\u00e8rement b\u00e9n\u00e9fique chez les patients atteints de BPCO car permettrait de r\u00e9duire la dur\u00e9e de ventilation m\u00e9canique invasive, la dur\u00e9e d'hospitalisation, le recours \u00e0 la trach\u00e9otomie, et serait associ\u00e9e \u00e0 une moindre fr\u00e9quence de complications et une meilleure survie chez ces patients [38] .",
            "cite_spans": [
                {
                    "start": 274,
                    "end": 277,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 438,
                    "end": 442,
                    "text": "[37,",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 443,
                    "end": 446,
                    "text": "38]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 624,
                    "end": 627,
                    "text": "[7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 628,
                    "end": 631,
                    "text": "38]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 885,
                    "end": 889,
                    "text": "[38]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 1055,
                    "end": 1059,
                    "text": "[39]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 1225,
                    "end": 1229,
                    "text": "[39]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 1849,
                    "end": 1853,
                    "text": "[38]",
                    "ref_id": "BIBREF37"
                }
            ],
            "ref_spans": [],
            "section": "Autres traitements"
        },
        {
            "text": "Les indications de la ventilation m\u00e9canique (intubation trach\u00e9ale) sont r\u00e9sum\u00e9es dans l'encadr\u00e9 2 [22] . En cas d'exacerbation s\u00e9v\u00e8re, il est \u00e9galement n\u00e9cessaire de corriger d'\u00e9ventuels troubles m\u00e9taboliques, de commencer une ",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 102,
                    "text": "[22]",
                    "ref_id": "BIBREF21"
                }
            ],
            "ref_spans": [],
            "section": "Autres traitements"
        },
        {
            "text": "Dans plusieurs pays, des \u00e9tudes randomis\u00e9es ont \u00e9valu\u00e9 la possibilit\u00e9 d'un retour \u00e0 domicile pr\u00e9coce (d\u00e8s la sortie des urgences ou apr\u00e8s une tr\u00e8s courte hospitalisation) de malades ayant des crit\u00e8res d'hospitalisation mais sans crit\u00e8re de gravit\u00e9 imm\u00e9diate justifiant la r\u00e9animation et/ou la ventilation non invasive. Le retour \u00e0 domicile \u00e9tait rendu possible par la mise en place d'un dispositif multidisciplinaire similaire \u00e0 celui de l'hospitalisation \u00e0 domicile (HAD) : suivi infirmier rapproch\u00e9, kin\u00e9sith\u00e9rapie respiratoire, oxyg\u00e9noth\u00e9rapie et n\u00e9bulisations de bronchodilatateurs [7] . Le m\u00e9decin traitant \u00e9tait averti du retour au domicile de son patient, mais un autre m\u00e9decin assurait la prise en charge de cette HAD. De telles strat\u00e9gies ne sont effectivement pas d\u00e9l\u00e9t\u00e8res pour le devenir des malades et s'av\u00e8rent co\u00fbtefficaces [40, 41] . Pour le moment, il n'y a pas suffisamment de donn\u00e9es pour s\u00e9lectionner avec pr\u00e9cision les patients les plus aptes \u00e0 b\u00e9n\u00e9ficier de cette prise en charge \u00e0 domicile [7] . Par ailleurs, on peut assister au d\u00e9veloppement des services en sant\u00e9, avec comme exemple, le programme d'accompagnement du retour \u00e0 domicile des patients hospitalis\u00e9s (PRADO). Il s'agit d'un programme de la Caisse nationale d'assurance maladie existant pour d'autres pathologies chroniques, qui est en cours de d\u00e9ploiement pour la BPCO. Ses objectifs sont d'anticiper les besoins du patient li\u00e9s \u00e0 son retour \u00e0 domicile et de fluidifier le parcours h\u00f4pital-ville du patient.",
            "cite_spans": [
                {
                    "start": 586,
                    "end": 589,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 839,
                    "end": 843,
                    "text": "[40,",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 844,
                    "end": 847,
                    "text": "41]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 1013,
                    "end": 1016,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Strat\u00e9gies visant \u00e0 r\u00e9duire les hospitalisations ou leur dur\u00e9e"
        },
        {
            "text": "Enfin, la t\u00e9l\u00e9m\u00e9decine et le t\u00e9l\u00e9monitoring ont \u00e9t\u00e9 \u00e9valu\u00e9s dans la gestion \u00e0 domicile des patients atteints de BPCO stade II ou III avec au moins une exacerbation dans l'ann\u00e9e pr\u00e9c\u00e9dente. Il s'agissait de surveiller \u00e0 domicile diff\u00e9rents param\u00e8tres parmi lesquels la fr\u00e9quence cardiaque, la saturation en oxyg\u00e8ne, la temp\u00e9rature, l'activit\u00e9 physique, les sympt\u00f4mes respiratoires et l'observance des traitements. Ces \u00e9l\u00e9ments \u00e9taient t\u00e9l\u00e9transmis et analys\u00e9s par des m\u00e9decins qui pouvaient intervenir pour traiter au plus t\u00f4t des EA BPCO et ainsi \u00e9viter des passages aux urgences ou des hospitalisations. Certains travaux ont montr\u00e9 un b\u00e9n\u00e9fice du t\u00e9l\u00e9monitoring [42] [43] [44] , alors qu'une autre \u00e9tude n'a pas montr\u00e9 pas de diff\u00e9rence entre le bras t\u00e9l\u00e9m\u00e9decine et le bras contr\u00f4le [45] . Cette prise en charge semble int\u00e9ressante chez les patients les plus s\u00e9v\u00e8res. D'autres travaux prospectifs, randomis\u00e9s, avec de large effectifs sont n\u00e9cessaires pour d\u00e9finir au mieux la place de la t\u00e9l\u00e9m\u00e9decine chez les patients atteints de BPCO.",
            "cite_spans": [
                {
                    "start": 663,
                    "end": 667,
                    "text": "[42]",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 668,
                    "end": 672,
                    "text": "[43]",
                    "ref_id": "BIBREF42"
                },
                {
                    "start": 673,
                    "end": 677,
                    "text": "[44]",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 785,
                    "end": 789,
                    "text": "[45]",
                    "ref_id": "BIBREF44"
                }
            ],
            "ref_spans": [],
            "section": "Strat\u00e9gies visant \u00e0 r\u00e9duire les hospitalisations ou leur dur\u00e9e"
        },
        {
            "text": "Une r\u00e9\u00e9valuation est toujours n\u00e9cessaire au d\u00e9cours d'une EA BPCO. Le traitement de fond devra \u00eatre tout particuli\u00e8rement rediscut\u00e9 et adapt\u00e9 aux recommandations en vigueur [46] . Si l'exacerbation r\u00e9v\u00e8le la BPCO, un bilan spirom\u00e9trique et radiologique devra \u00eatre r\u00e9alis\u00e9 3 \u00e0 4 mois apr\u00e8s celle-ci [15] .",
            "cite_spans": [
                {
                    "start": 173,
                    "end": 177,
                    "text": "[46]",
                    "ref_id": "BIBREF45"
                },
                {
                    "start": 298,
                    "end": 302,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Au d\u00e9cours d'une EA BPCO"
        },
        {
            "text": "La r\u00e9cidive \u00e0 court terme d'une EA BPCO doit faire rechercher un foyer infectieux sous-jacent tel qu'un foyer dentaire (consultation sp\u00e9cialis\u00e9e et orthopantomogramme) ou sinusien (scanner des sinus \u00b1 nasofibroscopie ORL) [15] . Il faut savoir \u00e9galement \u00e9carter les diagnostics de cancer, cancer bronchique mais \u00e9galement ORL ou oesophagien, ainsi qu'une insuffisance cardiaque gauche, systolique ou diastolique, une maladie thromboembolique veineuse ou un syndrome d'apn\u00e9es obstructives du sommeil [15] .",
            "cite_spans": [
                {
                    "start": 222,
                    "end": 226,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 499,
                    "end": 503,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Au d\u00e9cours d'une EA BPCO"
        },
        {
            "text": "les auteurs d\u00e9clarent ne pas avoir de conflits d'int\u00e9r\u00eats en relation avec cet article.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D\u00e9claration d'int\u00e9r\u00eats"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "COPD exacerbations: defining their cause and prevention",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Wedzicha",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "A"
                    ],
                    "last": "Seemungal",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Lancet",
            "volume": "370",
            "issn": "",
            "pages": "786--96",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Prise en charge de la BPCO: recommandations pour la pratique clinique",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soci\u00e9t\u00e9 De Pneumologie De Langue Fran\u00e7aise",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Rev Mal Respir",
            "volume": "27",
            "issn": "",
            "pages": "1--76",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Susceptibility to exacerbation in chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Hurst",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Vestbo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Anzueto",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Locantore",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Mullerova",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Tal-Singer",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "N Engl J Med",
            "volume": "363",
            "issn": "",
            "pages": "1128--1166",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Projections of global mortality and burden of disease from 2002 to 2030",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Mathers",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Loncar",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "PLoS medicine",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Wedzicha",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "E"
                    ],
                    "last": "Brill",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Allinson",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "C"
                    ],
                    "last": "Donaldson",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "BMC Med",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "High-risk patients following hospitalisation for an acute exacerbation of COPD",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Piquet",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Chavaillon",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "David",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Martin",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Blanchon",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Roche",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Eur Respir J",
            "volume": "42",
            "issn": "",
            "pages": "946--55",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Exacerbations: etiology and pathophysiologic mechanisms",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Wedzicha",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Chest",
            "volume": "121",
            "issn": "",
            "pages": "136--177",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "New strains of bacteria and exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Sethi",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Grant",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "F"
                    ],
                    "last": "Murphy",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "N Engl J Med",
            "volume": "347",
            "issn": "",
            "pages": "465--71",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Recommandations pour la prise en charge de la BPCO : antibioth\u00e9rapie des exacerbations/d\u00e9compensations",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soci\u00e9t\u00e9 De Pneumologie De Langue Fran\u00e7aise",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Rev Mal Respir",
            "volume": "20",
            "issn": "",
            "pages": "65--73",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Pseudomonas aeruginosa in chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "F"
                    ],
                    "last": "Murphy",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Brauer",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Eschberger",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Lobbins",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Grove",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Am J Respir Crit Care Med",
            "volume": "177",
            "issn": "",
            "pages": "853--60",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors",
            "authors": [
                {
                    "first": "Tillie-Leblond I",
                    "middle": [],
                    "last": "Marquette",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Perez",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Scherpereel",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zanetti",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tonnel",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "B"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Ann Intern Med",
            "volume": "144",
            "issn": "",
            "pages": "390--396",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Comorbidities of COPD",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cavailles",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Brinchault-Rabin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Dixmier",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Goupil",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Gut-Gobert",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Marchand-Adam",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Eur Respir Rev",
            "volume": "22",
            "issn": "",
            "pages": "454--75",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Agusti",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "D"
                    ],
                    "last": "Edwards",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "I"
                    ],
                    "last": "Rennard",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Macnee",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Tal-Singer",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "Miller",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "PLoS One",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Recommandations pour la prise en charge de la BPCO : exacerbations: diagnostic, s\u00e9v\u00e9rit\u00e9 et prise en charge",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soci\u00e9t\u00e9 De Pneumologie De Langue Fran\u00e7aise",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Rev Mal Respir",
            "volume": "20",
            "issn": "",
            "pages": "56--64",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Wilkinson",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "C"
                    ],
                    "last": "Donaldson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Hurst",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "A"
                    ],
                    "last": "Seemungal",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Wedzicha",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Am J Respir Crit Care Med",
            "volume": "169",
            "issn": "",
            "pages": "1298--303",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "European Respiratory Society Guidelines on the use of nebulizers",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Boe",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Dennis",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "R"
                    ],
                    "last": "O&apos;driscoll",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "T"
                    ],
                    "last": "Bauer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Carone",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Dautzenberg",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Eur Respir J",
            "volume": "18",
            "issn": "",
            "pages": "228--270",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "R"
                    ],
                    "last": "Anthonisen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Manfreda",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "P"
                    ],
                    "last": "Warren",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "S"
                    ],
                    "last": "Hershfield",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "K"
                    ],
                    "last": "Harding",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "A"
                    ],
                    "last": "Nelson",
                    "suffix": ""
                }
            ],
            "year": 1987,
            "venue": "Ann Intern Med",
            "volume": "106",
            "issn": "",
            "pages": "196--204",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Miravitlles",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Kruesmann",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Haverstock",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Perroncel",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Choudhri",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Arvis",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Eur Respir J",
            "volume": "39",
            "issn": "",
            "pages": "1354--60",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Controlled trial of oral prednisone in outpatients with acute COPD exacerbation",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "H"
                    ],
                    "last": "Thompson",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "P"
                    ],
                    "last": "Nielson",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Carvalho",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "B"
                    ],
                    "last": "Charan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Crowley",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Am J Respir Crit Care Med",
            "volume": "154",
            "issn": "",
            "pages": "407--419",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "D"
                    ],
                    "last": "Aaron",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "L"
                    ],
                    "last": "Vandemheen",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hebert",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dales",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "G"
                    ],
                    "last": "Stiell",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ahuja",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "N Engl J Med",
            "volume": "348",
            "issn": "",
            "pages": "2618--2643",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "NIH and World Health Organization. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease",
            "authors": [],
            "year": 2014,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Oxygen therapy during exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Agusti",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Carrera",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Barbe",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Munoz",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Togores",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Eur Respir J",
            "volume": "14",
            "issn": "",
            "pages": "934--943",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "D"
                    ],
                    "last": "Moloney",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Kiely",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "T"
                    ],
                    "last": "Mcnicholas",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Lancet",
            "volume": "357",
            "issn": "",
            "pages": "526--534",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Mccrory",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Brown",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Cochrane Database Syst Rev",
            "volume": "4",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Niewoehner",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Erbland",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Deupree",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Collins",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "Gross",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Light",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "N Engl J Med",
            "volume": "340",
            "issn": "",
            "pages": "1941--1948",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Davies",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Angus",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Calverley",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Lancet",
            "volume": "354",
            "issn": "",
            "pages": "456--60",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Leuppi",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Schuetz",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bingisser",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bodmer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Briel",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Drescher",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "JAMA",
            "volume": "309",
            "issn": "",
            "pages": "2223--2254",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Effect of antimicrobial agents on the ecological balance of human microflora",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sullivan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Edlund",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "E"
                    ],
                    "last": "Nord",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Lancet Infect Dis",
            "volume": "1",
            "issn": "",
            "pages": "101--115",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Ciprofloxacin dosage and emergence of resistance in human commensal bacteria",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Fantin",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Duval",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Massias",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Alavoine",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Chau",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Retout",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Infect Dis",
            "volume": "200",
            "issn": "",
            "pages": "390--398",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "K"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mcgeer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "De Azavedo",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Low",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "N Engl J Med",
            "volume": "341",
            "issn": "",
            "pages": "233--242",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Garcia-Vidal",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Almagro",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Romani",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rodriguez-Carballeira",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Cuchi",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Canales",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Eur Respir J",
            "volume": "34",
            "issn": "",
            "pages": "1072--1080",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "H"
                    ],
                    "last": "Kuo",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Hsueh",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "C"
                    ],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Kuo",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Respirology",
            "volume": "12",
            "issn": "",
            "pages": "81--88",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Christ-Crain",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jaccard-Stolz",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bingisser",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Gencay",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Huber",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tamm",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Lancet",
            "volume": "363",
            "issn": "",
            "pages": "600--607",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Stolz",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Christ-Crain",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bingisser",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Leuppi",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Miedinger",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Muller",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Chest",
            "volume": "131",
            "issn": "",
            "pages": "9--19",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Troosters T. Rehabilitation and acute exacerbations",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Burtin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Decramer",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gosselink",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Janssens",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Eur Respir J",
            "volume": "38",
            "issn": "",
            "pages": "702--714",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Keenan",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Sinuff",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Cook",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "S"
                    ],
                    "last": "Hill",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Ann Intern Med",
            "volume": "138",
            "issn": "",
            "pages": "861--70",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Mechanical ventilation: invasive versus noninvasive",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Brochard",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Eur Resp J",
            "volume": "47",
            "issn": "",
            "pages": "31--37",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise (SPLF) et la Soci\u00e9t\u00e9 de r\u00e9animation de langue fran\u00e7aise (SRLF)",
            "authors": [],
            "year": 2006,
            "venue": "Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie-r\u00e9animation (SFAR)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "S"
                    ],
                    "last": "Ram",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Wedzicha",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wright",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Greenstone",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "BMJ",
            "volume": "329",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Hospital at home for acute exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Jeppesen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "G"
                    ],
                    "last": "Brurberg",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "E"
                    ],
                    "last": "Vist",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Wedzicha",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Wright",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Greenstone",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Cochrane Database Syst Rev",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "A home telemonitoring program reduced exacerbation and healthcare utilization rates in COPD patients with frequent exacerbations",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Alrajab",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "R"
                    ],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Owens",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Areno",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Caldito",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Telemed J",
            "volume": "18",
            "issn": "",
            "pages": "772--778",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Pedone",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Chiurco",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Scarlata",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Incalzi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "BMC Health Serv Res",
            "volume": "13",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "A home telehealth program for patients with severe COPD: the PROMETE study",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Segrelles Calvo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Gomez-Suarez",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Soriano",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Zamora",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gonzalez-Gamarra",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gonzalez-Bejar",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Respir Med",
            "volume": "108",
            "issn": "",
            "pages": "453--62",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Pinnock",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hanley",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Mccloughan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Todd",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Krishan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lewis",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "BMJ",
            "volume": "347",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Position of the French Language Society of Pulmonology regarding the 2011 version of the GOLD document",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Roche",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Rev Mal Respir",
            "volume": "29",
            "issn": "",
            "pages": "637--646",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Facteurs d\u00e9clenchant d'exacerbations de BPCO et m\u00e9canismes physiopathologiques associ\u00e9s entra\u00eenant l'augmentation des sympt\u00f4mes d\u00e9finissant l'exacerbation [1] BPCO : bronchopneumopathie chronique obstructive oraux et de la r\u00e9habilitation respiratoire [1]. Les traitements de fond pr\u00e9ventifs des EA BPCO sont d\u00e9taill\u00e9s ci-dessous.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Prise en charge ambulatoire des exacerbations de BPCO. Adapt\u00e9 des recommandations SPLF de 2003 [15] BPCO : bronchopneumopathie chronique obstructive.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Encadr\u00e9 1 : Signes cliniques et facteurs de gravit\u00e9 au cours d'une exacerbation de BPCO, imposant l'hospitalisation [7,15] Marbrures \u2022 OEd\u00e8mes des membres inf\u00e9rieurs \u2022 Tachycardie > 110/min Signes neurologiques \u2022 Agitation \u2022 Confusion \u2022 Obnubilation \u2022 Coma \u2022 Ast\u00e9rixis Autres facteurs \u2022 BPCO aux stades GOLD 3 et 4 \u2022 Patient sous oxyg\u00e9noth\u00e9rapie \u00e0 domicile \u2022 Installation brutale des sympt\u00f4mes \u2022 Comorbidit\u00e9(s) importante(s) \u2022 Doute diagnostique \u2022 \u00c2ge \u00e9lev\u00e9 \u2022 Absence de soutien familial \u00e0 domicile \u2022 Absence de r\u00e9ponse au traitement initial",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Encadr\u00e9 2 : Indications de la ventilation m\u00e9canique invasive (adapt\u00e9 des recommandations GOLD [22]) \u2022 \u00c9chec ou impossibilit\u00e9 de ventilation non invasive (VNI) \u2022 Arr\u00eat cardiaque ou respiratoire \u2022 Pauses respiratoires avec coma ou gasps \u2022 Inhalation massive \u2022 Encombrement bronchique majeur persistant \u2022 Fr\u00e9quence cardiaque < 50/min et perte de connaissance \u2022 \u00c9tat de choc \u2022 Arythmie ventriculaire s\u00e9v\u00e8re \u2022 Hypox\u00e9mie majeure chez patient instable et incapable de tol\u00e9rer la VNI anticoagulation pr\u00e9ventive et de mettre en place une kin\u00e9sith\u00e9rapie respiratoire.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}